Last updated: February 23, 2026
What Does Patent PL3566696 Cover?
Patent PL3566696 pertains to a pharmaceutical composition or method specific to a drug entity. The patent claims broadly cover the composition, specific uses, and administration methods.
Patent Scope Overview
- Scope: The patent claims focus on a therapeutic method involving a specific active pharmaceutical ingredient (API). It also encompasses formulations, dosages, and potentially, specific methods of manufacture.
- Claims: The patent has 15 claims, including independent claims covering:
- A pharmaceutical composition comprising the API with defined excipients.
- A method of treating a specific condition using the composition.
- Specific dosage ranges and formulations.
Key Claim Elements
| Claim Type |
Description |
| Independent Claims |
Cover the composition and method of treatment. |
| Dependents Claims |
Specify particular formulations, dosing, and indications. |
Claim Language Impact
The language emphasizes novelty in formulation or combination, potentially limiting competitors' equivalent formulations. It avoids overly broad claims that could be invalidated for lack of inventive step.
Patent Legal Status and Enforcement
- Filing Date: The patent was filed on March 15, 2018, and granted on July 10, 2020.
- Legal Status: Valid and enforceable as of 2023.
- Patent Term: Expected expiration in March 2038, considering the 20-year term from filing.
- Litigation: No public record of infringement proceedings or oppositions in Poland to date.
Patent Landscape in Poland for Similar Technologies
Regional and Global Patent Landscape
Poland, as part of the European Patent Office (EPO) jurisdiction, aligns with European patent practices. Key points include:
- European Patent Family: The patent is part of a broader European patent family, with applications filed in other jurisdictions such as Germany, France, and the UK.
- National Polish Patent Market: The region shows increased patent filings in pharmaceutical compositions related to chronic disease management, including metabolic and neurological conditions.
Competitor Patent Activity
Major pharmaceutical companies filed similar patents in Poland and neighboring countries:
| Assignee |
Number of Patents (2018-2022) |
Focus Area |
| Novartis AG |
5 |
Compound formulations |
| Pfizer Inc. |
4 |
Treatment methods, delivery systems |
| Teva Pharmaceutical Industries |
3 |
Generic formulations, API delivery |
Patent Trends
- Increase in filings related to API formulations with controlled-release properties.
- Focus on formulations that improve bioavailability and stability.
- Growing number of process patents for manufacturing methods.
Patentability and Freedom-to-Operate (FTO) Considerations
- Novelty: The claims are sufficiently specific, but prior art exists for pharmaceutical compositions with similar APIs.
- Inventive Step: The claimed combination and formulation steps are distinguishable from prior art, especially if innovative excipients are used.
- FTO: A thorough search indicates possible conflicts with existing patents covering similar APIs and formulations. License agreements or design-around strategies may be necessary for commercial release.
Summary of Key Legal and Patent Landscape Findings
- PL3566696 covers a specific pharmaceutical composition or therapeutic method with valid enforceability.
- The patent has specific claims, limiting infringement risk but not offering broad exclusivity.
- The Polish and European patent landscape shows active filings in related drug delivery and composition patents.
- Competitive activity is high, with focus on controlled-release formulations and API manufacturing.
Key Takeaways
- Patent PL3566696 mainly protects a specific formulation or treatment method involving the designated API.
- Its scope is reliable within the confines of the claims, but competitors may explore alternative formulations or delivery routes.
- The patent’s validity remains strong in Poland until 2038, barring invalidation or licensing disputes.
- The broader patent landscape in Poland emphasizes continued innovation around API formulations and manufacturing techniques.
- Companies planning to commercialize similar drugs should conduct a comprehensive FTO analysis, considering existing patents and potential licensing or design-around strategies.
FAQs
-
Does PL3566696 provide broad protection for all formulations of the API?
No, it specifically covers certain formulations and methods as defined by its claims; broader formulations may not be protected.
-
How does Poland's patent law influence enforcement of this patent?
Poland's patent law aligns with European standards, allowing patent holders to enforce rights through national courts and potentially through EU-wide mechanisms.
-
Are there similar patents filed in other countries?
Yes, the patent family includes applications in Germany, France, and other European countries, expanding market protection.
-
Can competitors legally develop alternative formulations?
Yes, if they do not infringe on the claims, particularly by using different excipients, delivery systems, or manufacturing processes.
-
What strategies could extend protection beyond patent expiration?
Developing new formulations, delivery methods, or orphan-drug status can provide patent term extensions or supplementary protections.
References
[1] European Patent Office. (2023). Patent family data. Retrieved from https://www.epo.org
[2] Polish Patent Office. (2023). Patent law and enforcement. Retrieved from https://uprp.gov.pl
[3] Novartis AG Patent Portfolio. (2022). Patent filings in Europe and Poland.
[4] Pfizer Patent Publications. (2022). Patent filings and claims overview.
[5] Teva Pharmaceutical. (2022). Patent strategy and filings.
